All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Results from a single-center, retrospective analysis comparing blinatumomab + tyrosine kinase inhibitors (TKIs) vs pediatric-inspired chemotherapy + TKI protocols in 47 patients with Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) were recently published in the International Journal of Cancer by Stolz et al.
Key data: Despite patients in the blinatumomab cohort being significantly older (p < 0.05) and having higher rates of active central nervous system (CNS) disease, overall survival (OS), progression-free survival (PFS), and non-relapse mortality (NRM) were comparable between patients treated with blinatumomab + TKI vs conventional chemotherapy + TKI regimens (2 year-OS, 87% vs 78%; PFS, 81% vs 54%; NRM, 6.3% vs 14%, respectively). Severe treatment-related adverse events (TRAEs) were significantly more common in the chemotherapy group than the blinatumomab cohort.
Key learning: Blinatumomab + TKI represents a safe and effective chemotherapy-free approach for patients with de novo or relapsed Ph+ B-ALL, offering comparable survival outcomes with significantly reduced treatment-related toxicity compared with standard chemotherapy-based regimens.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content